Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ilaria Vigliotta
Observed names:
I. Vigliotta,
Vigliotta, Ilaria
Institution:
Istituto di Ematologia di Bologna
Observed institutions:
University Hospital Heidelberg,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto di Ematologia di Bologna,
University of Florence,
University of Bologna
ORCID:
0000-0002-5491-1315
Observed ORCID:
0000-0002-5491-1315
OpenAlex ID:
A5086339138
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022
·
M. Martello
, A. Poletti
, et al.
·
Blood Cancer Journal
·
47
PDF
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
2024
·
Marina Martello
, Vincenza Solli
, et al.
·
Blood Cancer Journal
·
24
Characterization of the Tissue and Stromal Cell Components of Micro-Superficial Enhanced Fluid Fat Injection (Micro-SEFFI) for Facial Aging Treatment
2018
·
Martina Rossi
, Barbara Roda
, et al.
·
Aesthetic Surgery Journal
·
23
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
2022
·
Ilaria Vigliotta
, Silvia Armuzzi
, et al.
·
Frontiers in Oncology
·
14
PDF
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features
2024
·
Carolina Terragna
, Andrea Poletti
, et al.
·
Nature Communications
·
13
Bispecific Antibodies and Cart in Multiple Myeloma: Appropriate Selection of Patients and Sequencing
2025
·
Michele Puppi
, Ilaria Sacchetti
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
12
PDF
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
2024
·
Enrica Borsi
, Ilaria Vigliotta
, et al.
·
Cells
·
11
PDF
The induction of -helical structure in partially unfolded HypF-N does not affect its aggregation propensity
2011
·
B. Ahmad
, I. Vigliotta
, et al.
·
Protein Engineering Design and Selection
·
10
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients
2024
·
Ilaria Vigliotta
, Vincenza Solli
, et al.
·
Cancers
·
9
PDF
Effective Label-Free Sorting of Multipotent Mesenchymal Stem Cells from Clinical Bone Marrow Samples
2022
·
Silvia Zia
, Carola Cavallo
, et al.
·
Bioengineering
·
9
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients
2023
·
Enrica Borsi
, Gaia Mazzocchetti
, et al.
·
Clinical and Experimental Medicine
·
7
PDF
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma
2025
·
Andrea Poletti
, Barbara Taurisano
, et al.
·
Haematologica
·
6
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment
2022
·
Chiara Sartor
, Mario Arpinati
, et al.
·
Hematological Oncology
·
6
BoBafit : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
2022
·
G. Mazzocchetti
, A. Poletti
, et al.
·
Computational and Structural Biotechnology Journal
·
5
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?
2025
·
M. Talarico
, S. Barbato
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
4
PDF
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients
2022
·
Marina Martello
, Vincenza Solli
, et al.
·
International Journal of Molecular Sciences
·
2
PDF
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
2026
·
Stefania Oliva
, Marina Martello
, et al.
·
Cancer Medicine
·
1
OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading
2021
·
Marina Martello
, Andrea Poletti
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
DB CPCs RRMM
2026
·
Ilaria Vigliotta
·
Zenodo (CERN European Organization for Nuclear Research)
OA-36 Longitudinal Liquid Biopsy Monitoring Reveals Distinct Residual Disease Dynamics Beyond Bone Marrow MRD Assessment in Newly Diagnosed Multiple Myeloma
2026
·
Carolina Terragna
, Vincenza Solli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-051 Beyond Consensus Genomic Staging: Genomic Heterogeneity of Relapsed Standard-Risk Multiple Myeloma
2026
·
Viola Meixian Vuong
, Vincenza Solli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-026 An Integrated High-Sensitivity Flow Cytometry Platform Revealing Dissemination-Associated Phenotypes and Therapeutic Target Heterogeneity in Multiple Myeloma: The MMulticolors Panel
2026
·
Alessia Varacalli
, Ilaria Vigliotta
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-285 Longitudinal ctDNA Profiling Enables Early Detection of Relapse and Clonal Dynamics in Multiple Myeloma
2026
·
Marina Martello
, Gaia Mazzocchetti
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
LBA-26 High-Sensitivity Longitudinal Circulating Plasma Cells Monitoring After T-Cell-Redirecting Therapies: The Impact of Early Clearance on Response and Survival Outcomes
2026
·
Ilaria Vigliotta
, Alessia Varacalli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-500 TP53 Isoform Switching Defines Functional States and Clinical Risk in Multiple Myeloma
2026
·
Enrica Borsi
, Alessandra Vitale
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
48
Citation count:
204
H-index:
9
I10-index:
8
Year
Topic
Type